Literature DB >> 12410906

Use of lipid-lowering drugs in older adults with and without dementia: a community-based epidemiological study.

Eric G Rodriguez1, Hiroko H Dodge, Maria A Birzescu, Gary P Stoehr, Mary Ganguli.   

Abstract

OBJECTIVES: To compare the use of lipid-lowering drugs in community-dwelling older adults with and without dementia.
DESIGN: Comparison of lipid-lowering drug use by demented cases and nondemented controls based on secondary analysis of data from a longitudinal epidemiologic study.
SETTING: Longitudinal study of a largely rural, low- socioeconomic-status, community-based cohort of older persons residing in the mid-Monongahela Valley of South-west Pennsylvania (the Monongahela Valley Independent Elders Survey). PARTICIPANTS: Eight hundred forty-five individuals of mean +/- standard deviation (SD) age of 80.5 +/- 4.6, participating in the fifth biennial wave of data collection. MEASUREMENTS: Demographics; medical history; medication regimen (including examination of prescription bottle labels); self-report of most recent visit to primary care physician (PCP); and standardized clinical assessment to determine presence of dementia, including Clinical Dementia Rating (CDR).
RESULTS: One hundred seventy participants (20.1% of total subject cohort) had dementia, with a CDR of 0.5 or greater. Mean ages of demented and nondemented individuals were 83.5 +/- 5.1 and 79.8 +/- 4.2, respectively. Similar proportions, 87.7% and 89.5%, of these groups reported PCP visits in the previous year. Of the total sample, 9.4% (3.5% of the demented and 10.8% of the nondemented) were taking lipid-lowering drugs. After adjustment for age, sex, education, visit with PCP within the past year, and potential confounding clinical and lifestyle variables (self-reported heart disease, stroke or transient ischemic attacks, hypertension, smoking, and alcohol consumption), dementia was associated with a lower likelihood of taking a lipid-lowering drug (odds ratio = 0.39, 95% confidence interval = 0.16-0.95). In post hoc subgroup analyses, similar results were found when restricting lipid-lowering drugs to statins alone but were not statistically significant. Drug use was not associated with severity of dementia (CDR = 0.5 vs CDR >or= 1).
CONCLUSIONS: Demented individuals were less likely than their nondemented counterparts to be taking lipid-lowering drugs. This finding could reflect different prescribing patterns by physicians for demented and nondemented patients or a possible protective effect of these drugs against dementia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12410906     DOI: 10.1046/j.1532-5415.2002.50515.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  30 in total

1.  Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action.

Authors:  Eugenio Barone; Giovanna Cenini; Fabio Di Domenico; Sarah Martin; Rukhsana Sultana; Cesare Mancuso; Michael Paul Murphy; Elizabeth Head; D Allan Butterfield
Journal:  Pharmacol Res       Date:  2010-12-27       Impact factor: 7.658

2.  Increased atherogenic lipoproteins are associated with cognitive impairment: effects of statins and subclinical atherosclerosis.

Authors:  Cynthia M Carlsson; David M Nondahl; Barbara E K Klein; Patrick E McBride; Mark A Sager; Carla R Schubert; Ronald Klein; Karen J Cruickshanks
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Jan-Mar       Impact factor: 2.703

3.  Use of statins and risk of hospitalization with dementia: a Danish population-based case-control study.

Authors:  Henriette Thisted Horsdal; Anne Vingård Olesen; Christiane Gasse; Henrik Toft Sørensen; Robert C Green; Søren Paaske Johnsen
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Jan-Mar       Impact factor: 2.703

4.  Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers.

Authors:  Alberto Serrano-Pozo; Gloria L Vega; Dieter Lütjohann; Joseph J Locascio; Marsha K Tennis; Amy Deng; Alireza Atri; Bradley T Hyman; Michael C Irizarry; John H Growdon
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Jul-Sep       Impact factor: 2.703

Review 5.  Preventing Alzheimer's disease : separating fact from fiction.

Authors:  Mary Sano; Hillel Grossman; Kathleen Van Dyk
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 6.  Neuropsychiatric adverse events associated with statins: epidemiology, pathophysiology, prevention and management.

Authors:  Marco Tuccori; Sabrina Montagnani; Stefania Mantarro; Alice Capogrosso-Sansone; Elisa Ruggiero; Alessandra Saporiti; Luca Antonioli; Matteo Fornai; Corrado Blandizzi
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

Review 7.  Statins and dementia.

Authors:  Lewis H Kuller
Journal:  Curr Atheroscler Rep       Date:  2007-08       Impact factor: 5.113

Review 8.  The Janus face of the heme oxygenase/biliverdin reductase system in Alzheimer disease: it's time for reconciliation.

Authors:  Eugenio Barone; Fabio Di Domenico; Cesare Mancuso; D Allan Butterfield
Journal:  Neurobiol Dis       Date:  2013-10-02       Impact factor: 5.996

9.  Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study.

Authors:  C Cramer; M N Haan; S Galea; K M Langa; J D Kalbfleisch
Journal:  Neurology       Date:  2008-07-29       Impact factor: 9.910

10.  On cholesterol levels and statins in cognitive decline and Alzheimer disease: progress and setbacks.

Authors:  Marwan N Sabbagh; Kabir Thind; David Larry Sparks
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Oct-Dec       Impact factor: 2.703

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.